Predict your next investment

HEALTHCARE | Disease Diagnosis

See what CB Insights has to offer

Founded Year

2020

Stage

Spinoff / Spinout | Alive

About Infinity BiologiX

Infinity BiologiX analyzes the genetic causes of common, complex diseases to discover diagnoses, treatments, and cures.

Infinity BiologiX Headquarter Location

New Brunswick, New Jersey,

United States

Latest Infinity BiologiX News

Infinity BiologiX and Cytox collaborate to provide new genetic test to predict the risk of cognitive decline due to Alzheimer’s ...

Jun 24, 2021

Powered by Cytox’s genoSCORE, the new test enables physicians to support patients with lifestyle changes, and guide possible use of drug therapy, to delay the onset of disease symptoms PISCATAWAY, N.J. & OXFORD, England & MANCHESTER, England--( BUSINESS WIRE )--Today, Infinity BiologiX, LLC (IBX) and Cytox Ltd, announce a collaboration to provide a new, non-invasive, genetic test that can predict the risk of cognitive decline due to Alzheimer’s through a simple saliva or blood sample. The product is anticipated to be available to physicians in the coming months. Physicians can use the genoSCORE test to assess patients before symptoms arise, and prior to invasive cerebrospinal fluid (CSF) testing or expensive scanning techniques. Furthermore, the test’s simplicity of use enables elderly and vulnerable patients not able to attend healthcare settings, to provide a sample from home. Dr. Richard Pither, CEO of Cytox, commented: “Alzheimer’s disease affects over 46 million people in the world1. We see this new test as a powerful tool to enable physicians to make immediate decisions about their patients’ risk of cognitive decline due to Alzheimer’s disease, and guide them towards effective lifestyle and therapeutic interventions that can have a significant impact on delaying the onset of disease symptoms and cognitive decline2. We are delighted to be working with IBX, a leading provider of laboratory tests that can bring this new product to US physicians and their patients.” Robin Grimwood, IBX CEO, explained, “We see this agreement for the sale and distribution of the genoSCORE-powered test as a critical collaboration in line with our mission to understand the genetic causes of common, complex diseases, such as Alzheimer’s, and to discover diagnoses, treatments and, support the development of new, effective therapeutic interventions for these diseases.” News Source:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.